Detecting Hyperglycemia Using Biomarkers Versus Continuous Glucose Monitoring
Authors' conclusion
Glycated albumin and fructosamine had similar associations with CGM-defined metrics of hyperglycemia compared with HbA1c. These three biomarkers performed similarly in the detection of time above range and in range. Our results provide evidence for the utility of glycated albumin and fructosamine as alternate measures of hyperglycemia.
Study context
- Population
- Adults aged 30–97 years with diabetes wearing a continuous glucose monitor (CGM) for up to 2 weeks; mean age 74 years, 53% women, 36% Black
- Participants
- 552 adults
- Outcome
- Correlation with CGM mean glucose
Methodological detailspooled cross-sectional analysis
- Pooled cross-sectional analysis
Main finding
As reported in the abstract
| Group | R |
|---|---|
| Hemoglobin A1c (HbA1c) | 0.72 |
| Glycated albumin | 0.64 |
| Fructosamine | 0.64 |
R
Hemoglobin A1c (HbA1c)0.72
Glycated albumin0.64
Fructosamine0.64
Observational data: associations, not effects.
Further findings
Correlation with TAR (>180 mg/dL)
- Results were similar for time above range (>180 mg/dL)
Detection of target TIR and TAR
- Glycated albumin and fructosamine performed similarly to HbA1c; c-statistics range
- 0.85 to 0.94
CGM glycemia
- Median of mean CGM glucose
- 132 mg/dL
- Mean time in range (70-180 mg/dL)
- 84%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Detecting Hyperglycemia Using Biomarkers Versus Continuous Glucose Monitoring. Diabetes Care. Published 12 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →